Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 May 9;9(1):7144.
doi: 10.1038/s41598-019-43638-0.

Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling

Affiliations
Comparative Study

Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling

Paola Di Benedetto et al. Sci Rep. .

Abstract

Systemic Sclerosis (SSc) is a disease with limited therapeutic possibilities. Mesenchymal stem cells (MSCs)-therapy could be a promising therapeutic option, however the ideal MSCs source has not yet been found. To address this problem, we perform comparison between bone marrow (BM)-MSCs and adipose (A)-MSCs, by the miRs expression profile, to identify the gene modulation in these two MSCs source. MicroRNAs (miRs) are RNAs sequences, regulating gene expression and MSCs, derived from different tissues, may differently respond to the SSc microenvironment. The miRs array was used for the miRs profiling and by DIANA-mirPath tool we identified the biological functions of the dysregulated miRs. In SSc-BM-MSCs, 6 miRs were significantly down-regulated and 4 miRs up-regulated. In SSc-A-MSCs, 11 miRs were significantly down-regulated and 3 miRs up-regulated. Interestingly, in both the sources, the involved pathways included the senescence mechanisms and the pro-fibrotic behaviour. Furthermore, both the MSCs sources showed potential compensatory ability. A deeper knowledge of this miRs signature might give more information about some pathogenic steps of the disease and in the same time clarify the possible therapeutic role of autologous MSCs in the regenerative therapy in SSc.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
MiRs volcano plots. MiRs volcano plots of SSc-BM-MSC (A,B) and SSc-A-SSC (C,D). MicroRNAs’ distribution, obtained from TaqMan array human microRNA set A (in A,C) and set B (in B,D) was reported. In green are reported all the miRs down regulated, in red all the miRs up-regulated. Analyses were performed by using Expression Suite software. Y axis: p value (−log10), p = 0,05 threshold in blue. X axis: fold change (log2), black vertical lines indicate 0,5 (left) and 2 (right) fold change.
Figure 2
Figure 2
Venn diagram. Venn diagram shows the numbers of miRs expressed in Profile BM (blue) and the numbers of miRs expressed in Profile A (red). The Profile BM and Profile A do not share any miRs expression.
Figure 3
Figure 3
Graphical visualization of miRNA-target interactions. Neo4J software graphical visualization of miRNA-target interactions, concerning the Profile BM (left) and Profile (right) A. Red circles represent miRNAs. Blue circles represent genes that interact with the miRs, experimentally supported in TarBase. Purple circles represent the relevant pathways, that include validated target genes. Both the Profile BM and Profile A share “TGF-beta Signalling Pathway” and “Signaling Pathways Regulating Pluripotency Of Stem Cells”.

Similar articles

Cited by

References

    1. Altorok N, Wang Y, Kahaleh B. Endothelial dysfunction in systemic sclerosis. Curr Opin Rheumatol. 2014;26:615–620. doi: 10.1097/BOR.0000000000000112. - DOI - PubMed
    1. Cipriani P, et al. The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. J Rheumatol. 2015;42:1808–1816. doi: 10.3899/jrheum.150088. - DOI - PubMed
    1. Cipriani P, et al. Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features. Arthritis Res Ther. 2014;16:442. doi: 10.1186/s13075-014-0442-z. - DOI - PMC - PubMed
    1. Di Benedetto P, et al. Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. Arthritis Res Ther. 2018;20:223. doi: 10.1186/s13075-018-1719-4. - DOI - PMC - PubMed
    1. Cipriani P, et al. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther. 2015;17:247. doi: 10.1186/s13075-015-0754-7. - DOI - PMC - PubMed

Publication types